ZEPBOUND (AUTOINJECTOR)

Growth

tirzepatide

NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
21

Mechanism of Action

G-Protein-linked Receptor Interactions

Pharmacologic Class:

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

Clinical Trials (5)

NCT07438444Phase 4Not Yet Recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Started Mar 2026
344 enrolled
Diabetes Mellitus, Type 2ObesityOverweight
NCT07191873Phase 4Not Yet Recruiting

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Started Feb 2026
60 enrolled
Idiopathic Intracranial Hypertension (IIH)
NCT07299084Phase 1Recruiting

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

Started Jan 2026
40 enrolled
Diabetes Mellitus, Type 2OverweightObesity
NCT07364175N/ARecruiting

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

Started Jan 2026
60 enrolled
HypertensionObesity & Overweight
NCT06651177Phase 2Recruiting

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Started Dec 2025

Loss of Exclusivity

LOE Date
Jul 22, 2039
162 months away
Patent Expiry
Jul 22, 2039
Exclusivity Expiry
Dec 20, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
9474780
Jan 5, 2036
SubstanceProduct
11357820
Jun 14, 2039
Product
11918623
Jun 14, 2039
U-3855
12453756
Jun 14, 2039
Product
12343382
Jul 22, 2039
U-4409